Urushiol Induces Apoptosis via a p53-dependent Pathway in Human Gastric Cancer Cells

Kim, Seaho; Kim, Dong Hwan; Lee, Sun Hwa; Kim, Min Jeong; Yoon, Ju-Duk; Chung, Hae Young; Na, Chun Soo; Kim, Nam Deuk

doi:10.15430/jcp.2013.18.2.169

Cited by 7 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, even after minimum exposure time (4 hours), the NE-loaded Myricetin also showed a considerable reduction in clonogenic survival, validating its long-term inhibition effect in TNBC cells (Fig 6D .). Earlier research reported that mitochondrial dysfunction and the BAX/Bcl-2 dependent pathway drive Myricetin-induced apoptosis in cancer cells [41,42]. Consistent with these findings, Myr-NE showed significant upregulation in Bax/Bcl-2 ratio and a substantial decrease in Bcl-XL as compared to Myricetin alone (Fig 6B -C.).…”

Section: Discussionsupporting

confidence: 86%

Nanoemulsion Myricetin preparation increases the anticancer efficacy against Triple-negative Breast Cancer cells

Sharma

Chaturvedi

Khan

et al. 2023

Preprint

View full text Add to dashboard Cite

Background and purpose: Myricetin (3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one) is a polyhydroxyfavonol compound widely found in nature has been shown to possess anticancer effects in various cancers. Despite its efficacy, poor water solubility and low oral bioavailability hinders its therapeutic application. To overcome these limitations, Nanoemulsion (NE) emerged as a promising approach that combines the advantages of NE into a single delivery system. The present study aimed to investigate the advantage of myricetin loaded NE over and above native Myricetin. Experimental Approach: The nano-emulsion was formulated using Capryol 90 as oil, Tween 20 as a surfactant, and Transcutol HP as a co-surfactant. Further comparative analysis of Myricetin and nano-emulsified Myricetin (Myr-NE) were carried out in triple negative breast cancer (MDA-MB-231) cells for anticancer activity. Key results: The optimized Myr-NE had a zeta potential of -6.35±0.3, an average particle size of 89.32±2.8 nm, PDI of 0.105±0.02, and a spherical shape as confirmed in transmission electron microscopy. Diffusion-dominant drug release was observed with 95.49±2.84 % Drug release for 24hrs, 2-fold higher than Myr-suspension. When nano-emulsified, Myricetin exhibited efficient inhibition of cell proliferation, clonogenicity, and increased apoptosis with IC50 of 37 µM, a dose ~2.5 fold lower than native Myricetin. Mechanistic insights reveal that Myr-NE induced more ROS generation and considerably inhibited AKT and mTOR activation, leading to enhanced anticancer activity. Conclusions & Implications: In conclusion, these findings suggest that the therapeutic efficacy of Myricetin significantly improved through a novel Myr-NE formulation which may be a promising therapeutic approach for treating TNBC.

show abstract

Section: Discussionsupporting

confidence: 86%

Nanoemulsion Myricetin preparation increases the anticancer efficacy against Triple-negative Breast Cancer cells

Sharma

Chaturvedi

Khan

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…S. H. Han et al also reported that in breast cancer, myricetin induces apoptosis via the MAPK pathway [19]. In addition, some researchers have noted that myricetin induced apoptosis through an increase in BAX/BCL2 ratio and by AIF release from mitochondria into the cytosol [21]. However, in our study, myricetin promoted apoptosis through the PARP/caspase3 pathway.…”

Section: Discussioncontrasting

confidence: 59%

“…This indicates that myricetin, as a dietary hormone, only kills cancer cells without killing normal cells, and certifies myricetin as a natural medicine with the potential to treat OC. Several studies have shown that myricetin has anti-tumor effects against gastric, breast, and colorectal cancer et al [18][19][20][21]. It has been shown that myricetin induces apoptosis and cell cycle arrest in gastric cancer cells via Ribosomal S6 kinase 2 and Mad1 [18].…”

Section: Discussionmentioning

confidence: 99%

Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer

Yang,

Lan,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Ovarian cancer (OC) is the second most common gynecological malignancy and has a high mortality rate. The current chemotherapeutic drugs have the disadvantages of drug resistance and side effects. Myricetin, as a kind of natural medicine, has the advantages of easy extraction, low price, and few side effects. Numerous studies have demonstrated the anti-cancer properties of myricetin. However, the underlying effect of myricetin on ovarian cancer remains to be elaborated. Therefore, this study was aimed to application of in vivo and in vitro studies to reveal the mechanism of myricetin suppresses TGF-β-induced epithelial-to-mesenchymal (EMT) in OC. Method: n vitro experiments were conducted to evaluate the effects of myricetin on cell proliferation and apoptosis using CCK8 assay, plate clonal formation assay, and flow cytometry. The expression levels of caspase-3, PARP, and the MAPK/ERK and PI3K/AKT signaling pathways were assessed using western blotting. Wound healing and transwell, western blot and immunofluorescence assay were used to detect TGF-β-induced cell migration, invasion, EMT and the levels of Smad3, MAPK/ERK, PI3K/AKT signaling pathways. Additionally, a mouse xenograft model was established to verify the effects of myricetin on OC in vivo. Results: Myricetin inhibited the proliferation of ovarian cancer through MAPK/ERK and PI3K/AKT signaling pathways, promoted the apoptosis through the Caspase-3 and PARP signaling pathways in vitro and attenuated OC progression and metastasis in vivo. Moreover, myricetin reversed TGF-β-induced EMT through Smad3, MAPK/ERK and PI3K/AKT signaling pathway. Conclusion: Myricetin demonstrated inhibitory effects on OC progression and metastasis both in vivo and in vitro. It also reversed TGF-β-induced EMT through the classical and non-classical Smad signaling pathways.

show abstract

“…Despite an allergic reaction to urushiol, Rhus verniciflua Stokes has been traditionally used for the treatment of abdominal masses in Korea (Yoo and Roh, 1977). In addition, numerous studies have reported that urushiol exhibits various beneficial activities such as anti-oxidant ( Kim et al ., 1997 ), anti-microbial ( Suk et al ., 2011 ), and anti-cancer activities ( Choi et al ., 2001 ; Kim et al ., 2013 ). We isolated four urushiols (urushiol I, urushiol II, urushiol III, and urushiol V) from cortex of Rhus verniciflua Stokes.…”

Section: Discussionmentioning

confidence: 99%

Urushiol V Suppresses Cell Proliferation and Enhances Antitumor Activity of 5-FU in Human Colon Cancer Cells by Downregulating FoxM1

Jeong

Ryu

2022

Biomol Ther (Seoul)

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common malignant tumor. 5-FU is commonly used for the treatment of CRC. However, the development of drug resistance in tumor chemotherapy can seriously reduce therapeutic efficacy of 5-FU. Recent data show that FoxM1 is associated with 5-FU resistance in CRC. FoxM1 plays a critical role in the carcinogenesis and drug resistance of several malignancies. It has been reported that urushiol V isolated from the cortex of Rhus verniciflua Stokes is cytotoxic to several types of cancer cells. However, the underlying molecular mechanisms for its antitumor activity and its potential to attenuate the chemotherapeutic resistance in CRC cells remain unknown. Here, we found that urushiol V could inhibit the cell proliferation and induced S-phase arrest of SW480 colon cancer cells. It inhibited protein expression level of FoxM1 through activation of AMPK. We also investigated the combined effect of urushiol V and 5-FU. The combination treatment reduced FoxM1 expression and consequently reduced cell growth and colony formation in 5-FU resistant colon cancer cells (SW480/5-FUR). Taken together, these result suggest that urushiol V from Rhus verniciflua Stokes can suppress cell proliferation by inhibiting FoxM1 and enhance the antitumor capacity of 5-FU. Therefore, urushiol V may be a potential bioactive compound for CRC therapy.

show abstract

Urushiol Induces Apoptosis via a p53-dependent Pathway in Human Gastric Cancer Cells

Cited by 7 publications

References 21 publications

Nanoemulsion Myricetin preparation increases the anticancer efficacy against Triple-negative Breast Cancer cells

Nanoemulsion Myricetin preparation increases the anticancer efficacy against Triple-negative Breast Cancer cells

Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer

Urushiol V Suppresses Cell Proliferation and Enhances Antitumor Activity of 5-FU in Human Colon Cancer Cells by Downregulating FoxM1

Contact Info

Product

Resources

About